MedTrace Logo

Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma

NCT06772740 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2025-05-28

No results posted yet for this study

Summary

COMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle meningeal artery embolization for chronic subdural hematoma.

Conditions

  • Endovascular Treatment
  • Chronic Subdural Hematoma

Interventions

PROCEDURE

Middle meningeal artery embolization

Middle meningeal artery embolization within 7 days after randomization

Sponsors & Collaborators

  • Kazutaka Uchida

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-23
Primary Completion
2027-08-31
Completion
2029-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06772740 on ClinicalTrials.gov